ASH 2023: Nonmalignant Hematology

CE / CME

Key Studies in Nonmalignant Hematology Disorders: Independent Conference Coverage of ASH 2023

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: February 22, 2024

Expiration: February 21, 2025

Catherine M. Broome
Catherine M. Broome, MD

Activity

Progress
1 2
Course Completed

Introduction

In this activity, Catherine M. Broome, MD, reviews a few key studies for nonmalignant hematologic disorders that were reported at the 2023 American Society of Hematology (ASH) Annual Meeting, including novel therapies for sickle cell disease (SCD), paroxysmal nocturnal hemoglobinuria (PNH), and cold agglutinin disease (CAD).

Please note that the slide thumbnails in this activity link to PowerPoint slidesets that also can be found here, each focused on the specific study or topic of interest. These slidesets also may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: Once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with a hematologic disorder or malignancy do you provide care for in a typical month?

The international, open-label, phase I/II REACH trial evaluated the maximum tolerated dose (MTD) of hydroxyurea in pediatric patients (aged 1-10 years) with sickle cell anemia (SCA) in Sub-Saharan Africa. Which of the following outcomes was reported for patients enrolled in this study treated with the MTD of hydroxyurea followed by dose optimization based on complete blood counts (CBC)?

Data from the APPLY-PNH study of iptacopan as first therapy or switch from anti-C5 therapy (eg, eculizumab or ravulizumab) presented at ASH 2023 reported positive data for improved hemoglobin and transfusion avoidance in patients with PNH. Which of the following would be the optimal way of applying iptacopan in the clinic based on the recent approval for this agent?

Which of the following best describes the results from the long-term analysis of the phase III ALPHA trial of add-on danicopan vs placebo to standard anti─C5 therapy in patients with PNH and clinically significant extravascular hemolysis (csEVH)?